Wel­come to End­points News’ man­u­fac­tur­ing briefs, where we bring you es­sen­tial news on new builds, col­lab­o­ra­tions, re­calls and more.

Astellas is the latest large pharmaceutical company to ink a deal with a Chinese biotech, paying $130 million upfront for a Claudin18.2-targeted antibody-drug conjugate from Evopoint Biosciences.

Biopharma faces uncertainty in H2 2025 amid policy concerns and market challenges, with key healthcare conferences and medical meetings ahead to provide industry direction.

Intellia Therapeutics reports serious liver enzyme elevation in one patient during Phase 3 trial of nex-z gene editing therapy for ATTR cardiomyopathy; shares drop 26% ...

Eli Lil­ly’s ex­per­i­men­tal weight loss drug ap­pears to have set a new bar, help­ing obese pa­tients in a Phase II study lose 24% of their … ...

Ei­sai has slashed 2027 sales pro­jec­tions for its Bio­gen-part­nered Alzheimer’s treat­ment Leqem­bi by rough­ly half.

Unit­ed­Health Group’s Op­tum is shut­ting down its vir­tu­al care busi­ness, End­points News has learned. Known as Op­tum Vir­tu­al Care, the busi­ness pro­vides on­line ur­gent ...

Turn Biotech­nolo­gies, a start­up de­vel­op­ing mR­NA ther­a­pies to wind back the clock on ag­ing cells has ac­quired an ex­per­i­men­tal drug de­liv­ery tech­nol­o­gy from ...

Sarep­ta and Roche’s con­fir­ma­to­ry study for a Duchenne gene ther­a­py failed to hit its pri­ma­ry end­point, com­pli­cat­ing plans to con­vert the drug’s la­bel in­to a … ...

Eli Lil­ly will pay up to $1.925 bil­lion in cash for weight loss drug­mak­er Ver­sa­nis, mark­ing the Big Phar­ma’s fourth ac­qui­si­tion this sum­mer af­ter deals … ...

As­traZeneca is fur­ther in­vest­ing in Chi­na, open­ing an R&D cen­ter in Bei­jing and ink­ing a pair of ma­jor­ly back­loaded R&D deals with Chi­nese drug de­vel­op­ers … ...